Casimersen Patent Expiration
Casimersen is used for treating Duchenne Muscular Dystrophy (DMD) in patients with a mutation of the DMD gene amenable to exon 45 skipping. It was first introduced by Sarepta Therapeutics Inc
Casimersen Patents
Given below is the list of patents protecting Casimersen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Amondys 45 | US10287586 | Antisense molecules and methods for treating pathologies | Nov 12, 2030 | Sarepta Theraps Inc |
| Amondys 45 | US10781450 | Antisense molecules and methods for treating pathologies | Nov 12, 2030 | Sarepta Theraps Inc |
| Amondys 45 | US9228187 | Antisense molecules and methods for treating pathologies | Nov 12, 2030 | Sarepta Theraps Inc |
| Amondys 45 | US9758783 | Antisense molecules and methods for treating pathologies | Nov 12, 2030 | Sarepta Theraps Inc |
| Amondys 45 | USRE48960 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Feb 16, 2029 | Sarepta Theraps Inc |
| Amondys 45 | US8524880 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Apr 02, 2026 | Sarepta Theraps Inc |
| Amondys 45 | US9447415 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun 28, 2025
(Expired) | Sarepta Theraps Inc |
| Amondys 45 | US10533174 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
| Amondys 45 | US9416361 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
Casimersen's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List